


SHEET 1 of 3

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
066683/0190SERIAL NO.  
09/679,147APPLICANT  
Tomoki TodoFILING DATE  
October 5, 2000GROUP  
1614LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)Date Submitted to PTO: March 13, 2001

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO OR ABSTRACT

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Publisher and location, Etc.)

<i>AK</i>	A1	M. Albert, <i>et al.</i>	"Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs", The Rockefeller University, New York, NY, <i>Letters to Nature</i> , 392: 86-89 (1998)
	A2	S. Baskar, <i>et al.</i>	"Rejection of MHC Class II-Transfected Tumor Cells Requires Induction of Tumor-Encoded B7-1 and/or B7-2 Costimulatory Molecules", The American Association of Immunologists, Bethesda, MD, <i>The Journal of Immunology</i> , 156: 3821-3827 (1996)
	A3	F. Cavallo, <i>et al.</i>	"Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response", VCH Publishers, Inc. Deerfield Beach, FL, <i>European Journal of Immunology</i> , 25: 1154-1162 (1995)
	A4	P. Chaux, <i>et al.</i>	"Inflammatory Cells Infiltrating Human Colorectal Carcinomas Express HLA Class II but Not B7-1 and B7-2 Costimulatory Molecules of the T-Cell Activation", United States and Canadian Academy of Pathology, Inc., USA, <i>Laboratory Investigation</i> , 74: 975-983 (1996)
	A5	L. Chen, <i>et al.</i>	"Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-mediated Tumor Immunity", The Rockefeller University Press, New York, NY, <i>Journal of Experimental Medicine</i> , 179: 523-532 (1994)
	A6	R. Denfeld, <i>et al.</i>	"In Situ Expression of B7 and CD28 Receptor Families in Human Malignant Melanoma: Relevance for T-Cell-Mediated Anti-Tumor Immunity", Wiley-Liss, Inc., New York, NY, <i>International Journal of Cancer</i> , 62: 259-265 (1995)
	A7	F. Falkner, <i>et al.</i>	"Escherichia coli gpt Gene Provides Dominant Selection for Vaccinia Virus Open Reading Frame Expression Vectors", American Society for Microbiology, Washington, DC, <i>Journal of Virology</i> , 62: 1849-1854 (1988)

EXAMINER


DATE CONSIDERED

12/14/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## SHEET 2 of 3

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)Date Submitted to PTO: March 13, 2001ATTY DOCKET NO.  
066683/0190SERIAL NO.  
09/679,147APPLICANT  
Tomoki TodoFILING DATE  
October 5, 2000GROUP  
1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Publisher and location, Etc.)

A8	F. Falkner, <i>et al.</i>	"Transient Dominant Selection of Recombinant Vaccinia Viruses", American Society for Microbiology, Washington, DC, <i>Journal of Virology</i> , 64: 3108-3111 (1990)
A9	J. Galea-Lauri, <i>et al.</i>	"Novel costimulators in the immune gene therapy of cancer", Nature Publishing Group, New York, NY, <i>Cancer Gene Therapy</i> , 3: 202-214 (1996)
A10	J. Heuer, <i>et al.</i>	"Retrovirus-Mediated Gene Transfer of B7-1 and MHC Class II Converts a Poorly Immunogenic Neuroblastoma into a Highly Immunogenic One", Mary Ann Liebert, Inc., Larchmont, NY, <i>Human Gene Therapy</i> , 7: 2059-2068 (1996)
A11	A. Huang, <i>et al.</i>	"Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens", American Association for the Advancement of Science, Washington, DC, <i>Science</i> , 264: 961-965 (1994)
A12	E. Katsanis, <i>et al.</i>	"Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity", Nature Publishing Group, New York, NY, <i>Cancer Gene Therapy</i> 3: 75-82 (1996)
A13	E. Katsanis, <i>et al.</i>	"B7-1 Expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules", Nature Publishing Group, New York, NY, <i>Cancer Gene Therapy</i> , 2: 39-46 (1995)
A14	Y. Li, <i>et al.</i>	"Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors", The Rockefeller University Press, New York, NY, <i>Journal of Experimental Medicine</i> , 183: 639-644 (1996)
A15	S. Miyatake, <i>et al.</i>	"Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma", Nature Publishing Group, New York, NY, <i>Cancer Gene Therapy</i> , 4: 222-228 (1997)

EXAMINER


DATE CONSIDERED

12/14/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 3 of 3

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
066683/0190SERIAL NO.  
09/679,147APPLICANT  
Tomoki TodoFILING DATE  
October 5, 2000GROUP  
1614LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)Date Submitted to PTO: March 13, 2001

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Publisher and location, Etc.)

<i>AK</i>	A16	P. Mroz, <i>et al.</i>	"Retrovirally Transduced <i>Escherichia coli</i> gpt Genes Combine Selectability with Chemosensitivity Capable of Mediating Tumor Eradication", Mary Ann Liebert, Inc., Larchmont, NY, <i>Cancer Gene Therapy</i> , 4: 589-595 (1993)
	A17	D. Mueller, <i>et al.</i>	"Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway Determines the Outcome of T Cell Antigen Receptor Occupancy", Annual Reviews, Inc., Palo Alto, CA, <i>Annual Review of Immunology</i> , 7: 445-480 (1989)
	A18	I. Parney, <i>et al.</i>	"Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse-Human Glioblastoma Multiforme Model", Mary Ann Liebert, Inc., Larchmont, NY, <i>Human Gene Therapy</i> , 8: 1073-1085 (1997)
	A19	J. Rao, <i>et al.</i>	"IL-12 Is an Effective Adjuvant to Recombinant Vaccina Virus-Based Tumor Vaccines", The American Association of Immunologists, Bethesda, MD, <i>The Journal of Immunology</i> , 156: 3357-3365 (1996)
	A20	R. Schwartz, <i>et al.</i>	"T Cell Anergy", Scientific American, Inc., New York, NY, <i>Scientific American</i> , 62-71 (1993)
	A21	M. Toda, <i>et al.</i>	"In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity", The American Association of Immunologists, Bethesda, MD, <i>The Journal of Immunology</i> , 160: 4457-4464 (1996)
<i>q</i>	A22	L. Zitvogel, <i>et al.</i>	"Interlukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors", VCH Verlagsgesellschaft mbH, Weinheim, Germany, <i>European Journal of Immunology</i> , 26: 1335-1341 (1996)

EXAMINER

DATE CONSIDERED

*12/14/01*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
066683/0190SERIAL NO.  
09/679,147

APPLICANT

Tomoki Todo

FILING DATE

October 5, 2000

GROUP

1614

LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)Date Submitted to PTO: March 13, 2001



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	B1	WJR Hirst, <i>et al.</i>	"Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1", Stockton Press, Basingstoke, UK, <i>Gene Therapy</i> , 4: 691-699 (1997)
	B2	W. Marti, <i>et al.</i>	"Nonreplicating Recombinant Vaccina Virus Encoding Human B-7 Molecules Elicits Effective Costimulation of Naïve and Memory CD4 <sup>+</sup> T Lymphocytes <i>in Vitro</i> ", Academic Press, San Diego, CA, <i>Cellular Immunology</i> , 179: 146-152 (1997).
	B3	K. Sturmhoefel, <i>et al.</i>	"Potent Activity of Soluble B7-IgG Fusion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant", American Association for Cancer Research, Philadelphia, PA, <i>Cancer Research</i> , 59: 4964-4972 (1999)
	B4	H. Swiniarski, <i>et al.</i>	"Immune Response Enhancement by <i>in Vivo</i> Administration of B7.21g, a Soluble Costimulatory Protein", Academic Press, San Diego, CA, <i>Clinical Immunology</i> , 92: 235-245 (1999)
	B5	M. Moro, <i>et al.</i>	"Induction of Therapeutic T-Cell Immunity by Tumor Targeting with Soluble Recombinant B7-Immunoglobulin Costimulatory Molecules", American Association for Cancer Research, Philadelphia, PA, <i>Cancer Research</i> , 59: 2650-2656 (1999)
	B6	P. Challita-Eid, <i>et al.</i>	"A B7.1-Antibody Fusion Protein Retains Antibody Specificity and Ability to Activate Via the T Cell Costimulatory Pathway", The American Association of Immunologists, Bethesda, MD, <i>Journal of Immunology</i> , 160: 3419-3426 (1998)
	B7	R. Cristiano, <i>et al.</i>	"Targeted Non-Viral Gene Delivery for Cancer Gene Therapy", Frontiers in Bioscience, Manhasset, NY, <i>Frontiers in BioScience</i> , 3: 1161-1170 (1998)

EXAMINER

DATE CONSIDERED

12/14/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.